CUTANEOUS VASCULAR EFFECTS OF PULSED DYE LASER IN COMBINATION WITH BEVACIZUMAB

这个子项目是许多利用资源的研究子项目之一 由NIH/NCRR资助的中心拨款提供。子项目的主要支持 而子项目的主要调查员可能是由其他来源提供的， 包括其它NIH来源。 列出的子项目总成本可能 代表子项目使用的中心基础设施的估计数量， 而不是由NCRR赠款提供给子项目或子项目工作人员的直接资金。 脉冲染料激光治疗血管病变对某些患者有效，但需要多次治疗，大多数患者无法完全清除。 我们已经确定了疗效有限的几个原因。 一个重要的问题是治疗后血管复发。 贝伐单抗是FDA批准的抗血管生成剂，可减少治疗后的血管复发。 目前的研究将使用小鼠背部皮褶模型，并将与Bernard Choi博士一起进行。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. Primary support for the subproject and the subproject's principal investigator may have been provided by other sources, including other NIH sources. The Total Cost listed for the subproject likely represents the estimated amount of Center infrastructure utilized by the subproject, not direct funding provided by the NCRR grant to the subproject or subproject staff. Pulsed dye laser treatment of vascular lesions is effective for some patients but multiple treatments are required and most patients do not achieve complete clearance. We have defined several reasons for limited efficacy. One important issue is vessel recurrence after treatment. Bevacizumab is an FDA approved anti-angiogenic agent which might diminish vessel recurrence post-treatment. Current investigations will use a mouse dorsal skinfold model and will be performed with Dr. Bernard Choi.